SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to recent revenue growth and speculation around a potential crypto treasury strategy, sparking significant after-hours volatility. The community is actively debating the stock's low float and potential for a short squeeze, with some cautioning against chasing the spike. Discussions also include the company's compliance status and potential catalysts for further upward movement.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending following news of a $5 million production order, signaling a move from R&D to commercialization and revenue generation, a key milestone for the company. Community members are discussing the potential for further purchase orders and partnerships, particularly highlighting the connection to Luxshare and Meta, and expecting substantial growth in the AI infrastructure market. While some express concerns about market volatility and dilution, the overall sentiment remains optimistic about POET's long-term prospects in the photonics space.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community reminisces about the stock's past volatility and discusses potential short squeezes, drawing comparisons to other meme stocks like $BYND. A recent White House post using GameStop's slogan has further fueled the conversation and speculative interest. Traders are actively debating potential price movements and the influence of market makers.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, potential rate cuts, and possible S&P 500 inclusion. The community is bullish, fueled by optimism around growth prospects, crypto offerings, and increasing membership. Many see a breakout above the $30 resistance level and are discussing potential price movements post-earnings.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following news of a potential acquisition by Novartis, with the deal speculated to strengthen Novartis's neuroscience pipeline. The community is buzzing about the potential buyout price, the value of the spin-off company, and the implications for the broader RNA therapeutics sector. Some traders point to options activity as a signal and congratulate long-term holders.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors react to news of Larvotto Resources rejecting its acquisition offer, with community discussions focusing on the deal's potential restructuring and the company's intrinsic value. Despite the setback, many express confidence in UAMY's fundamentals, citing existing contracts and potential government support amid increasing geopolitical tensions around critical mineral supply chains. The community is weighing the short-term bearish sentiment against the long-term potential of UAMY in the antimony market.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss the potential for a short squeeze, fueled by high borrow rates and a tightly held float. Community members are actively debating share allocation and the impact of recent insider buying, while closely monitoring short interest data. Sentiment suggests retail investors are optimistic about a potential breakout.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential acquisition by INCY and compare it to competitor KURA, particularly focusing on the safety profiles of their respective leukemia treatments. Community members are weighing the impact of a recent FDA approval for Syndax's Revuforj against concerns over a "black box" warning, while also evaluating future revenue potential and possible buyout scenarios.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending following strong earnings and forward guidance, sparking a wave of analyst upgrades and price target increases. The community is focused on the company's growth prospects, particularly within its platform strategy and the potential impact of its acquisition of CyberArk. Bullish sentiment is fueled by PANW's leadership in cybersecurity and its transition towards AI-driven solutions.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates its listing on Kraken, with discussions focusing on potential price movements and the long-term vision of the project. Some community members are drawing comparisons to XRP and highlighting Zebec's partnerships and regulatory compliance, while others express skepticism and caution against unrealistic expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial was conducted by &nbsp;Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris.</li><li>The company said that once daily oral 50 mg Denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints in the study.&nbsp;</li><li>Ascletic said in October that it plans to submit a new drug application to China National Medical Products Administration for Denifanstat for the treatment of moderate-to-severe acne soon. &nbsp;</li></ul>Shares of Sagimet Biosciences Inc. (SGMT) soared 22% by Friday afternoon after its Denifanstat drug yielded positive results in the treatment of acne in a late-stage trial.The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. It was aimed at evaluating the safety and efficacy of Denifanstat in acne treatment.<h2 class="st-heading-2">Trial Takeaways</h2>Acne vulgaris is a common skin condition caused by clogged hair follicles from oil and dead skin cells, which can result in whiteheads, blackheads, pimples, and in severe cases, painful nodules and cysts.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sagimet.com/news-releases/news-release-details/denifanstat-achieved-all-endpoints-treatment-moderate-severe">said</a> that once daily oral 50 mg Denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints. Primary endpoints included the percentage change in total lesion count, and the percentage change in inflammatory lesion count, among others.At week 12, treatment success rates with Denifanstat were more than double those of placebo, with marked reductions in both inflammatory and non-inflammatory lesions, it noted.Furthermore, the drug was generally well-tolerated, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Ascletis said in October that it plans to soon submit a new drug application to China National Medical Products Administration for Denifanstat for the treatment of moderate-to-severe acne.Sagimet, meanwhile, is studying the drug in the treatment of metabolic dysfunction associated steatohepatitis, a serious form of liver disease, characterized by fat buildup, inflammation, and liver cell damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SGMT"> SGMT stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="SGMT's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SGMT's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded positive on the stock, citing the size of the Chinese market.<stembedurl>https://stocktwits.com/Mikrus36/message/633613843</stembedurl>SGMT stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gm-reportedly-lays-off-over-200-employees-days-after-raising-2025-earnings-guidance/cLGJFcKR3tb">GM Reportedly Lays Off Over 200 Employees Days After Raising 2025 Earnings Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study

The trial was conducted by  Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris.

Equity

<ul class="summary-bullets"><li>The new customer account represents one of INBS's most significant UK commercial deployments to date, the company said.</li><li>Intelligent Bio’s Intelligent Fingerprinting Drug Screening System uses fingerprint sweat analysis to identify recent use of drugs commonly found in the workplace.</li><li>Intelligent Bio is currently seeking FDA clearance to enter the U.S. workplace testing market beyond the Forensic Use Only category.</li></ul>Shares of Intelligent Bio Solutions (INBS) jumped over 1% on Thursday morning after the company announced that it has secured a major new contract with one of UK's largest industrial service providers for its drug testing technology.The unnamed company has operations across the energy, defense, nuclear, and industrial sectors and employs over 30,000 people globally, Intelligent Bio said. In the UK and Ireland alone, the company employs approximately 3,000 staff across multiple sites, it added.<h2 class="st-heading-2">Contract Details</h2>The new customer account represents one of INBS's most significant UK commercial deployments to date, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/23/3172035/0/en/Intelligent-Bio-Solutions-Secures-Major-UK-Contract-with-Multinational-Industrial-Service-Provider.html">said.</a> The medical technology stated that the adoption of its drug testing technology is part of the customer’s initiative to enhance workforce compliance and intended to replace the existing testing process based on urine collection and third-party testing.Intelligent Bio’s Intelligent Fingerprinting Drug Screening System is expected to reduce downtime, increase productivity, and deliver rapid results at point of testing through fingerprint sweat analysis. The technology screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. It provides results in under ten minutes.<blockquote>“Securing this account highlights the expanding market confidence in our technology and its growing role in transforming drug testing across some of the world's largest industrial operators.” -Harry Simeonidis, CEO, Intelligent Bio Solutions</blockquote><h2 class="st-heading-2"> Plans Ahead</h2>Intelligent Bio is currently seeking FDA clearance to enter the U.S. workplace testing market beyond the Forensic Use Only category.The category "Forensic Use Only" applies to testing devices that have not been cleared by the U.S. Food and Drug Administration (FDA) for clinical or over-the-counter use. Instead, these products are intended exclusively for use by law enforcement.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around INBS jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBS's Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>INBS's Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user said that they are bullish on the long term outlook for the stock.<stembedurl>https://stocktwits.com/Chrisssss1/message/633407341</stembedurl>Another applauded the contract, terming it a sign of demand.<stembedurl>https://stocktwits.com/louter_genieten/message/633398481</stembedurl><a href="https://stocktwits.com/symbol/INBS">INBS stock</a> is down by 28% this year and by about 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Intelligent Bio Solutions Stock Rises On New Contract For Drug Testing Technology

The new customer account represents one of INBS's most significant UK commercial deployments to date, the company said.

Shares of Achieve Life Sciences, Inc. (ACHV) soared 32% on Friday afternoon after the company said that the U.S. Food and Drug Administration (FDA) awarded the company a Commissioner's National Priority Voucher (CNPV) for its Cytisinicline.The voucher is only available to nine programs in the program’s inaugural year. The program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.Achieve Life Sciences’ Cytisinicline is indicated for nicotine e-cigarette or vaping cessation. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168544/0/en/Achieve-Life-Sciences-Receives-FDA-Commissioner-s-National-Priority-Voucher-for-Cytisinicline-for-Treatment-of-Nicotine-Dependence-for-E-cigarette-or-Vaping-Cessation.html">said</a>.In a mid-stage trial, participants treated with Cytisinicline were found to be 2.6 times more likely to quit using nicotine e-cigarettes or vapes compared to placebo. The FDA has agreed on a late-stage trial design that, together with the mid-stage data, would support an application for approval in vaping cessation.In September, the FDA accepted the company’s application for Cytisinicline as a treatment for smoking cessation. The agency is expected to decide on the application by June 20, 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_1_41_17_PM_png_6eea8f50e0.webp" alt="ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>Other drugs awarded the voucher under the FDA program include Merck Group’s infertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy Teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and more.ACHV stock is up by 15% this year and down by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a 13 year old schoolboy holds single-use Vapes for Recycling in Kingston on Thames, England. (Photo by Peter Dazeley/Getty Images)

Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.

Veritone (VERI) stock became the third-most trending ticker on Stocktwits, and its shares fell nearly 17% in early trading after the company announced an equity offering of approximately 12.87 million shares of common stock&nbsp;at a purchase price of $5.83 per share.Notably, despite the slide, the stock was still trading at $6.98 at the time of writing.&nbsp;The aggregate gross proceeds from the offering are expected to be about $75 million, before deducting offering expenses payable by the company.&nbsp;Veritone said that it intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes. The company said this could also include capital expenditures, debt service, and repayment of indebtedness.Retail sentiment on Veritone remained unchanged in the ‘extremely bullish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Tuesday, the company announced that it has secured major contract wins to deploy its Veritone Data Refinery (VDR) product offering. The firm also reported preliminary third-quarter results and said it expects revenue of $28.5 million to $28.7 million, compared with the prior forecast of $28 million to $30 million.Veritone also said it is now estimating an adjusted loss of $5.5 million to $6 million, compared to its initial expectation of an adjusted loss of $6.5 million to $6 million.<a href="https://stocktwits.com/symbol/VERI">Shares of Veritone</a> have gained over 121% this year and have jumped 74.5% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/above-food-stock-becomes-top-trending-ticker-on-stocktwits/ch6pPOfR3nm">Above Food Stock Becomes Top Trending Ticker On Stocktwits, Draws Massive Retail Interest After Breaking Out Above $5-Mark In October</a>

Why Did Veritone Stock Fall 17% Today?

Veritone said the purchase price is $5.83 per share in a registered direct offering, and the aggregate gross proceeds from the offering are expected to be about $75 million, before deducting offering expenses payable by the company. 

Shares of autonomous-vehicle (AV) technology company Cyngn, Inc. (CYN)&nbsp;rose over 0.50% in early premarket trading on Wednesday, suggesting they could witness follow-on buying after two consecutive sessions of gains.The strong rally in<a href="https://stocktwits.com/symbol/CYN">&nbsp;Cyngn stock</a> on Tuesday came after the company announced a<a href="https://stocktwits.com/news-articles/markets/equity/why-is-cyngn-stock-surging-22-percent-pre-market-today/ch6mo2wR3mL">&nbsp;commercial DriveMod Tugger deployment</a> with PepsiCo's (PEP) largest independent bottler in the U.S., G&amp;J Pepsi.&nbsp; DriveMod is Cyngn's autonomous vehicle technology that transforms industrial vehicles, such as forklifts and tuggers, into self-driving robots.Following the news, retail trader buzz&nbsp;surged, overwhelming the Cyngn stream on Stocktwits with messages. The message volume change on the Cyngn stream spiked 11,500% over the 24 hours leading up to late Tuesday. On Stocktwits, retail sentiment improved to 'extremely bullish' (87/100) as of early Wednesday, from 'bullish' the day before.<figure class="image"><img style="aspect-ratio:621/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_4_36_40_AM_png_0bbfe8acb5.webp" alt="Screenshot 2025-10-15 at 4.36.40 AM.png" width="621" height="53"><figcaption>CYN sentiment and message volume as of 4:35 a.m. ET, Oct. 15 | source: Stocktwits</figcaption></figure>A bullish user noted that the partnerships with Pepsi and Nvidia will provide Cyngn with cash for the next two years. In June, the company said its autonomous industrial vehicles, built on Nvidia&nbsp; Isaac and powered by DriveMod software, were currently operating in commercial environments to reduce labor costs, increase throughput, and improve safety.<stembedurl>https://stocktwits.com/kitir92/message/632357308</stembedurl>Another user expected the stock to trade above $10 on Wednesday.<stembedurl>https://stocktwits.com/time4themoon/message/632349740</stembedurl>Cyngn stock is down about 96% year-to-date, grossly underperforming the broader market. According to Koyfin, the average price target for the stock is $12, suggesting roughly 110% upside from current levels. Cyngn stock has traded in a 52-week range of $3.62-$1,312.50.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/asml-stock-rises-premarket-after-q3-results/ch6nYiSR3Zy">ASML Stock Rises Premarket After Q3 Results: Margin Outlook Raised On AI Chip Boom</a>

 In this photo illustration, the Cyngn logo is seen displayed on a smartphone screen.

Cyngn Stock Eyes Third Day Of Gains: What's Driving The Buzz?

Cyngn stock is down about 96% year-to-date, grossly underperforming the broader market.

Shares of Emerson Radio, one of the oldest consumer electronics manufacturers in the U.S., rose 20% in after-market trading on Wednesday after a sharp rally in recent sessions, piquing the interest of retail investors.The&nbsp;<a href="https://stocktwits.com/symbol/MSN">MSN stock</a> rose 65% in the previous two sessions to&nbsp;close at&nbsp;its highest level in over three years, without an apparent catalyst. The company is listed on the NYSE American, a platform for trading shares of small- and micro-cap companies operated by NYSE, and had a market cap of $15.7 million as of Wednesday.<figure class="image"><img style="aspect-ratio:614/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_11_44_09_AM_png_14d0034d6d.webp" alt="Screenshot 2025-10-09 at 11.44.09 AM.png" width="614" height="71"><figcaption>MSN sentiment and message volume as of October 9 | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for the stock shifted to nearly the highest possible level, 'extremely bullish' (98/100) as of early Thursday, up from 'neutral' two days prior.&nbsp;Over the past 24 hours, the message volume for the ticker increased by 278%, while the number of watchers on Stocktwits jumped by 18%.Several users reported buying shares, adding the stock to their watchlists, and forecasting a price level of $2 or more in the coming days."$MSN Anything below $1 is a buy here," said one user.<stembedurl>https://stocktwits.com/InterstellerRides/message/631603439</stembedurl>New Jersey-based Emerson Radio produces and sells a range of home appliances, including microwave ovens, refrigerators, fans, clock radios, Bluetooth speakers, and televisions.Year-to-date, the company's shares have gained 77.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on October 04, 2023 in New York City. 

Micro-Cap Emerson Radio Stock Surges By Two-Thirds In 2 Days, And Then Some More, Piquing Retail Traders

The home appliance company's shares snagged nearly the highest possible sentiment reading on Stocktwits.

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html">announced</a> a $25 million investment from CK Life Sciences, expected to be used to advance the clinical development of its lead microRNA asset called TTX-MC138 into a mid-stage clinical trial. The candidate is believed to be a master regulator of metastatic cancer across multiple indications.Shares of the company soared 55% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNAZ">RNAZ stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Polynoma is developing a late-stage candidate called seviprotimut-L, a vaccine aimed at melanoma patients who have limited options in stage IIB and IIC.“Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," TransCode’s new CEO, Philippe Calais, said.TransCode on Wednesday also announced that Calais has been appointed as the company CEO while remaining Chairman of the Board of Directors. Tom Fitzgerald stepped down as Interim CEO but remains CFO, it added.While there are no other changes to TransCode’s executive team, the company expects to retain several finance, development, and manufacturing professionals from Polynoma, it added.RNAZ stock is down by 87% this year and by 97% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stifel-hikes-price-target-on-tesla-after-fsd-v14-roll-out/ch6EKRbR3i9">Stifel Hikes Price Target On Tesla After FSD V14 Roll Out, Reiterates Hopes In Robotaxi</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Shares of Skye Bioscience, Inc. (SKYE) dived 60% in the pre-market session on Monday after the company said that its Nimacimab alone did not cause weight loss as compared to placebo in a mid-stage trial.Preliminary analysis suggested that 200 mg of Nimacimab as a subcutaneous weekly dose was suboptimal as a monotherapy, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial">said</a>. The data, however, support the evaluation of higher dosing, the company said.Further, Nimacimab in combination with Novo Nordisk’s Semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to Semaglutide alone, the company said. The positive observation supports further studies where Nimacimab is used with other therapies, it added.The drug alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and no increases in neuropsychiatric adverse events reported resulting from treatment with Nimacimab, Skye said. Overall, the study, which enrolled 136 adults with overweight or obesity, had a discontinuation rate of 27%. Notably, 3.7% of the discontinuations were due to adverse events, with the placebo group contributing 60% of these discontinuations, according to the company.“With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials," said Puneet Arora, Chief Medical Officer of Skye Bioscience. The company is now evaluating the data to determine the next steps for the development of the drug.SKYE stock is up 68% this year and by about 24% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?

The company stated that its investigational drug alone did not cause weight loss compared to the placebo in a mid-stage trial. 

Should Vanguard Extended Market ETF (VXF) Be on Your Investing Radar?

Vanguard Group, Inc. - Vanguard Extended Market Index ETF

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF